TY - JOUR A1 - Trojan, Jörg A1 - Stintzing, Sebastian A1 - Haase, Oliver A1 - Koch, Christine A1 - Ziegler, Paul A1 - Demes, Melanie Christin A1 - Jelas, Ivan T1 - Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer T2 - The oncologist N2 - Background: Patients with colorectal carcinoma and high-grade microsatellite instability (MSI-H) or deficiency in mismatch repair (dMMR) exceptionally respond to immune checkpoint inhibitors (ICIs). ICIs are more active in treatment-naïve patients than in patients with refractory MSI-H/dMMR metastatic colorectal cancer and even more active in patients with locally advanced tumors. Material and Methods: A 33-year-old male patient with Lynch syndrome was diagnosed with a locally advanced rectal cancer and refused standard neoadjuvant chemoradiation because of the potential harm of sexual dysfunction. MMR and microsatellite instability status were analyzed by immunohistochemistry and fragment length polymerase chain reaction followed by capillary electrophoresis. Results: After MSI-H/dMMR was confirmed, the patient was treated with ICIs (1 mg/kg ipilimumab at day 1 and 3 mg/kg nivolumab at day 1 and 15). A complete clinical response was documented at day 21 after start of treatment. The patient underwent a total mesorectal excision at day 30. In the extirpated tissue, a complete pathological response was confirmed. Conclusion: In MSI-H/dMMR locally advanced rectal cancer short-course ICI treatment is highly effective and may be discussed in patients with dMMR locally advanced rectal cancer. Y1 - 2021 UR - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/64413 UR - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-644133 SN - 1549-490X N1 - Open access funding enabled and organized by Projekt DEAL. N1 - Early View: Online Version before inclusion in an issue VL - 2021 IS - online version before inclusion in an issue SP - 1 EP - 5 PB - Wiley CY - Hoboken, NJ ER -